About Annexin A1
Annexin A1 (ANXA1) is a protein
from Homo sapiens identified by UniProt accession
P04083, 346 residues long.
MolForge cross-references it against 0 known binders and
656 disease associations.
Target properties
| Protein name | Annexin A1 |
|---|
| UniProt accession | P04083 |
|---|
| Gene | ANXA1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 346 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (12)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (656)
Diseases linked to this target (Open Targets).
- breast adenocarcinoma · score 0.33
- annexin A1 measurement · score 0.32
- age at menarche · score 0.32
- brain volume measurement · score 0.31
- head and neck squamous cell carcinoma · score 0.25
- body height · score 0.23
- low grade glioma · score 0.23
- gastric adenocarcinoma · score 0.16
- cortical surface area measurement · score 0.14
- cutaneous melanoma · score 0.13
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P04083-F1 | alphafold | PREDICTED | 95.48 | — |
Amino-acid sequence (346 residues)
MAMVSEFLKQ AWFIENEEQE YVQTVKSSKG GPGSAVSPYP TFNPSSDVAA LHKAIMVKGV DEATIIDILT KRNNAQRQQI KAAYLQETGK PLDETLKKAL TGHLEEVVLA LLKTPAQFDA DELRAAMKGL GTDEDTLIEI LASRTNKEIR DINRVYREEL KRDLAKDITS DTSGDFRNAL LSLAKGDRSE DFGVNEDLAD SDARALYEAG ERRKGTDVNV FNTILTTRSY PQLRRVFQKY TKYSKHDMNK VLDLELKGDI EKCLTAIVKC ATSKPAFFAE KLHQAMKGVG TRHKALIRIM VSRSEIDMND IKAFYQKMYG ISLCQAILDE TKGDYEKILV ALCGGN
Explore Annexin A1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets